Ascendis Pharma AS (ASND) Insider buying
7 open-market purchases of ASND by Ascendis Pharma AS's executives and directors since May 2026, worth $684,733 in total, from SEC Form 4 filings.
Summary
The most recent: Jean Jacques Bienaime, Director bought $222,219 on August 14, 2026.
The biggest buyer over the period is Jean Jacques Bienaime (Director): 5 purchases, $607,003.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 7 | $684,733 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Jean Jacques Bienaime Director | 5 | $607,003 |
| Scott Thomas Smith EVP & Chief Financial Officer | 2 | $77,730 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Aug 14, 2026 | Jacques Bienaime Jean Director |
900 | $246.91 | $222,219 | Form 4 |
| Aug 14, 2026 | Jacques Bienaime Jean Director |
1,100 | $245.85 | $270,435 | Form 4 |
| Jun 2, 2026 | Thomas Smith Scott EVP & Chief Financial Officer |
100 | $219.00 | $21,900 | Form 4 |
| May 29, 2026 | Jacques Bienaime Jean Director |
100 | $223.50 | $22,350 | Form 4 |
| May 29, 2026 | Jacques Bienaime Jean Director |
200 | $223.76 | $44,752 | Form 4 |
| May 29, 2026 | Thomas Smith Scott EVP & Chief Financial Officer |
250 | $223.32 | $55,830 | Form 4 |
| May 26, 2026 | Jacques Bienaime Jean Director |
200 | $236.24 | $47,247 | Form 4 |
Questions about Ascendis Pharma AS
Are Ascendis Pharma AS insiders buying the stock?
7 open-market purchases of ASND by Ascendis Pharma AS's executives and directors since May 2026, worth $684,733 in total, from SEC Form 4 filings. The most recent: Jean Jacques Bienaime, Director bought $222,219 on August 14, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Ascendis Pharma AS's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.